prademagene zamikeracel Zevaskyn
Selected indexed studies
- Prademagene Zamikeracel. (, 2006) [PMID:40986686]
- Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. (Lancet, 2025) [PMID:40570869]
- Prademagene Zamikeracel. (Am J Health Syst Pharm, 2025) [PMID:40560535]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Prademagene Zamikeracel. (2006) pubmed
- Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. (2025) pubmed
- Prademagene Zamikeracel. (2025) pubmed
- Prademagene Zamikeracel: First Approval. (2025) pubmed
- FDA approval of prademagene zamikeracel (Zevaskyn): advancing gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) patients. (2026) pubmed
- Dystrophic Epidermolysis Bullosa. (1993) pubmed
- An evaluation of prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis bullosa. (2026) pubmed
- Prademagene zamikeracel (Zevaskyn) for recessive dystrophic epidermolysis bullosa. (2025) pubmed